These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 2840016)
1. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Barry AL; Jones RN; Thornsberry C Antimicrob Agents Chemother; 1988 May; 32(5):752-4. PubMed ID: 2840016 [TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Hardy DJ; Hensey DM; Beyer JM; Vojtko C; McDonald EJ; Fernandes PB Antimicrob Agents Chemother; 1988 Nov; 32(11):1710-9. PubMed ID: 3252753 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. Barry AL; Thornsberry C; Jones RN Antimicrob Agents Chemother; 1987 Feb; 31(2):343-5. PubMed ID: 2952064 [TBL] [Abstract][Full Text] [Related]
4. Postantibiotic effect of roxithromycin, erythromycin, and clindamycin against selected gram-positive bacteria and Haemophilus influenzae. Kuenzi B; Segessenmann C; Gerber AU J Antimicrob Chemother; 1987 Nov; 20 Suppl B():39-46. PubMed ID: 3501426 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae. Barry AL; Fuchs PC; Brown SD Eur J Clin Microbiol Infect Dis; 1997 Oct; 16(10):767-9. PubMed ID: 9405952 [TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of A-56268. Sefton AM; Maskell JP; Yong FJ; Chi SJ; Williams JD Eur J Clin Microbiol Infect Dis; 1988 Dec; 7(6):798-802. PubMed ID: 2975218 [TBL] [Abstract][Full Text] [Related]
7. Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin. Visalli MA; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1997 Sep; 41(9):1867-70. PubMed ID: 9303375 [TBL] [Abstract][Full Text] [Related]
8. Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis. Hoppe JE; Eichhorn A Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):653-4. PubMed ID: 2550234 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of midecamycin diacetate, a 16-membered macrolide, against Streptococcus pyogenes isolated in France, 1995-1999. Schlegel L; Merad B; Rostane H; Broc V; Bouvet A Clin Microbiol Infect; 2001 Jul; 7(7):362-6. PubMed ID: 11531981 [TBL] [Abstract][Full Text] [Related]
10. The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum. Felmingham D; Robbins MJ; Sanghrajka M; Leakey A; Ridgway GL Drugs Exp Clin Res; 1991; 17(2):91-9. PubMed ID: 1650694 [TBL] [Abstract][Full Text] [Related]
12. Comparative in-vitro activity of azithromycin and erythromycin against Gram-positive cocci, Haemophilus influenzae and anaerobes. Maskell JP; Sefton AM; Williams JD J Antimicrob Chemother; 1990 Jan; 25 Suppl A():19-24. PubMed ID: 2154433 [TBL] [Abstract][Full Text] [Related]
13. Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. Williams JD; Maskell JP; Shain H; Chrysos G; Sefton AM; Fraser HY; Hardie JM J Antimicrob Chemother; 1992 Jul; 30(1):27-37. PubMed ID: 1331019 [TBL] [Abstract][Full Text] [Related]
14. The in-vitro activity of CP-62,993 against Haemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococci. Dunkin KT; Jones S; Howard AJ J Antimicrob Chemother; 1988 Apr; 21(4):405-11. PubMed ID: 2837451 [TBL] [Abstract][Full Text] [Related]
15. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells. Stout JE; Arnold B; Yu VL J Antimicrob Chemother; 1998 Feb; 41(2):289-91. PubMed ID: 9533475 [TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients. Rolston KV; Ho DH; LeBlanc B; Bodey GP Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):30-3. PubMed ID: 2137413 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. Benson CA; Segreti J; Beaudette FE; Hines DW; Goodman LJ; Kaplan RL; Trenholme GM Antimicrob Agents Chemother; 1987 Feb; 31(2):328-30. PubMed ID: 2952063 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens. Dubois J; St -Pierre C Diagn Microbiol Infect Dis; 2001; 40(1-2):35-40. PubMed ID: 11448561 [TBL] [Abstract][Full Text] [Related]
20. Clarithromycin and azithromycin: new macrolide antibiotics. Piscitelli SC; Danziger LH; Rodvold KA Clin Pharm; 1992 Feb; 11(2):137-52. PubMed ID: 1312921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]